This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mallinckrodt Inks $1.3B Deal for Cadence

NEW YORK (The Deal) -- Dublin-based Mallinckrodt on Tuesday agreed to buy pain-fighting rival Cadence Pharmaceuticals (CADX) for $1.3 billion to tap growing interest in the target's acetaminophen treatment to relieve pain.

Mallinckrodt, which operates out of Hazelwood, Mo., said it would pay $14 per Cadence share, a 26% premium to the target's Monday close.

"We have been impressed with the strong relationships that Cadence's commercial organizations have established with customers in the hospital channel and are excited by the opportunity to build on these relationships to expand our platform in this area," said Mallinckrodt CEO and president Mark Trudeau in a statement.

The buyer is working to beef up its specialty pharmaceutical portfolio after being spun off last June by Dublin medical devices manufacturer Covidien. Mallinckrodt hopes it got in early on the development of Cadence's Ofirmev injectable acetaminophen, its only product.

Must Read: L'Oreal to Buy Up 8% Stake Held by Nestle

San Diego-based Cadence said the drug had estimated sales $110.5 million in 2013, more than double the $50.1 million in 2012. That number is expected to grow further since the drug only recently won approval for use in Canada.

Mallinckrodt also hopes the drug's position on the list of approved medications in 2,350 U.S. hospitals will give it leverage to sell its other treatments. The deal will immediately add to earnings, Mallinckrodt said.

Cadence had been seen as a potential acquisition target since it only offers a single product - most drug companies offer complete portfolios.

The deal is expected to close in March and Mallinckrodt said it would use loans from Deutsche Bank Securities and available cash for the purchase. Both boards are recommending the offer to shareholders and Mallinckrodt said it already has commitments from investors holding 13% of the target's stock.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CADX $0.00 0.00%
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs